These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35793409)

  • 41. Siltuximab for multicentric Castleman disease.
    Liu YC; Stone K; van Rhee F
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation.
    Lee YM; Choi YS; Kim JM
    Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
    Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine.
    Hoffmann C; Wechselberger T; Drexel H; Dertinger S; Dirnhofer S; Pierson SK; Fajgenbaum DC; Kessler A
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
    Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idiopathic multicentric Castleman disease and connective tissue disorder successfully treated by siltuximab: a pediatric case report.
    Hu S; Li Z; Zhang H; Li Y; Yang J; Ma Y; Chen L; Sun L; Zhai X
    Transl Pediatr; 2024 May; 13(5):824-832. PubMed ID: 38840677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
    Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
    Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
    van Rhee F; Rossi JF; Simpson D; Fosså A; Dispenzieri A; Kuruvilla J; Goh YT; Cho SG; Capra M; Liu T; Casper C; Cavet J; Wong RS
    Br J Haematol; 2021 Jan; 192(1):e28-e31. PubMed ID: 33128769
    [No Abstract]   [Full Text] [Related]  

  • 50. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
    Mukherjee S; Martin R; Sande B; Paige JS; Fajgenbaum DC
    Blood Adv; 2022 Jan; 6(2):359-367. PubMed ID: 34535010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant).
    Koga T; Takemori S; Hagimori N; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Dec; 99(50):e23291. PubMed ID: 33327255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease.
    Chrysochoou S; Kreft A; Schneider E
    Case Rep Hematol; 2022; 2022():1840589. PubMed ID: 35399163
    [No Abstract]   [Full Text] [Related]  

  • 54. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
    Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
    Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
    Prescrire Int; 2016 Mar; 25(169):61-4. PubMed ID: 27152394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
    Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
    Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
    van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
    J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idiopathic multicentric Castleman disease presenting progressive reticular honeycomb infiltration of lung and immunoglobulin G and immunoglobulin G4 dominant hypergammaglobulinemia: a case report.
    Kim HJ; Hong YH
    J Yeungnam Med Sci; 2022 Apr; 39(2):153-160. PubMed ID: 34218552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.